Your browser doesn't support javascript.
Population Health Management to identify and characterise ongoing health need for high-risk individuals shielded from COVID-19: a cross-sectional cohort study.
Kenward, Charlie; Pratt, Adrian; Creavin, Sam; Wood, Richard; Cooper, Jennifer A.
  • Kenward C; NHS Bristol, North Somerset and South Gloucestershire Clinical Commissioning Group, Bristol, UK charlie.kenward@nhs.net.
  • Pratt A; Department of Modelling and Analytics, NHS Bristol, North Somerset and South Gloucestershire Clinical Commissioning Group, Bristol, UK.
  • Creavin S; Department of Population Health Sciences, University of Bristol, Bristol, UK.
  • Wood R; Department of Modelling and Analytics, NHS Bristol, North Somerset and South Gloucestershire Clinical Commissioning Group, Bristol, UK.
  • Cooper JA; School of Management, University of Bath, Bath, UK.
BMJ Open ; 10(9): e041370, 2020 09 28.
Article in English | MEDLINE | ID: covidwho-808664
ABSTRACT

OBJECTIVES:

To use Population Health Management (PHM) methods to identify and characterise individuals at high-risk of severe COVID-19 for which shielding is required, for the purposes of managing ongoing health needs and mitigating potential shielding-induced harm.

DESIGN:

Individuals at 'high risk' of COVID-19 were identified using the published national 'Shielded Patient List' criteria. Individual-level information, including current chronic conditions, historical healthcare utilisation and demographic and socioeconomic status, was used for descriptive analyses of this group using PHM methods. Segmentation used k-prototypes cluster analysis.

SETTING:

A major healthcare system in the South West of England, for which linked primary, secondary, community and mental health data are available in a system-wide dataset. The study was performed at a time considered to be relatively early in the COVID-19 pandemic in the UK.

PARTICIPANTS:

1 013 940 individuals from 78 contributing general practices.

RESULTS:

Compared with the groups considered at 'low' and 'moderate' risk (ie, eligible for the annual influenza vaccination), individuals at high risk were older (median age 68 years (IQR 55-77 years), cf 30 years (18-44 years) and 63 years (38-73 years), respectively), with more primary care/community contacts in the previous year (median contacts 5 (2-10), cf 0 (0-2) and 2 (0-5)) and had a higher burden of comorbidity (median Charlson Score 4 (3-6), cf 0 (0-0) and 2 (1-4)). Geospatial analyses revealed that 3.3% of rural and semi-rural residents were in the high-risk group compared with 2.91% of urban and inner-city residents (p<0.001). Segmentation uncovered six distinct clusters comprising the high-risk population, with key differentiation based on age and the presence of cancer, respiratory, and mental health conditions.

CONCLUSIONS:

PHM methods are useful in characterising the needs of individuals requiring shielding. Segmentation of the high-risk population identified groups with distinct characteristics that may benefit from a more tailored response from health and care providers and policy-makers.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Risk Management / Coronavirus Infections / Risk Assessment / Pandemics / Health Information Systems / Population Health Management Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: BMJ Open Year: 2020 Document Type: Article Affiliation country: Bmjopen-2020-041370

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Risk Management / Coronavirus Infections / Risk Assessment / Pandemics / Health Information Systems / Population Health Management Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: BMJ Open Year: 2020 Document Type: Article Affiliation country: Bmjopen-2020-041370